Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Tuesday, March 31, 2015

Ocata Therapeutics Successfully Completes Dosing In Phase 1/2 RPE Studies

Ocata Therapeutics, Inc. , a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration and Stargardt's Macular Degeneration . A total of 38 patients have been safely dosed.

http://ift.tt/1NEMGsJ

No comments:

Post a Comment

Popular Stem Cell Roundup Posts